Neuroscience startup Vima Therapeutics extended its Series A financing by $40 million, bringing total raised to $100 million to fund clinical development of its muscarinic receptor antagonist program for movement disorders. The company said the follow‑on capital will support two Phase II trials in isolated dystonia and Parkinson’s disease. Vima’s lead candidate VIM0423 combines trihexyphenidyl with bethanechol to mitigate tolerability issues of muscarinic blockade, a strategy informed by historical use in Parkinson’s. Investors on the round include Atlas Venture, Frazier Life Sciences, Access Industries and Canaan Partners, reflecting broad VC interest in neurology assets with translational signal. Vima’s move to add Parkinson’s to its program followed early clinical proof‑of‑concept in dystonia and positions the company to pursue indications with shared hypercholinergic biology. The financing enables completion of ongoing trials and accelerates clinical development milestones.